Supplementary Table 1: Main Characteristics of Included Studies Authors Drug(s) Drug range Concomitant Study Time Number % Mean Comorbidities Patients Patients having Sponsor or anxiolytics duration considered of female Age having SOMNOLENCE mean (weeks) in our trial subjects INSOMNIA as side effect dosage as endpoint (ITT) as side effect (mg) (Abbasi et al. Sertraline + 200 No 6 T6 20 30 34.2±6.9 No 1 - No 2012)() Placebo (Abolfazli et al. Fluoxetine + 40 No 6 T6 22 50 33.3±6.1 No 5 - No 2011)() Placebo (Aguglia et al. Fluoxetine 28 Yes 8 T8 48 87.5 58.9±17.3 No 2 1 No 1993)() Sertraline 72 40 97.5 57.5±15.5 1 4 (Akhondzadeh Fluoxetine 60 No 6 T6 24 62.5 36.2±8.1 No 4 7 No et al. 2003)() (Akhondzadeh Fluoxetine + 40 No 6 T6 20 60 34.2±4.96 No 4 - No et al. 2009)() Placebo (Akkaya et al. Reboxetine 8 No 10 T10 50 74 40.4±10.7 No - 22 No 2006)() Venlafaxine 150 43 81.4 42.0±11.0 - 1 (Alvarez et al. Venlafaxine 225 Yes 6 T6 113 54.9 45.0±10.3 No 14 - Yes 2012)() Placebo 105 65.7 42.0±10.9 5 - (Amini et al. Fluoxetine 20 Yes 6 T6 15 60 37.7±11.3 No - 2 No 2005)() Mirtazapine 30 16 68.8 35.0±10.6 - 6 (Andreoli et al. Reboxetine 8-10 Yes 8 T8 126 67 40.0±.12.0 No 23 - No 2002)() Fluoxetine 20-40 127 65 40.0±.11.5 15 -
Supplementary Table 1: Main Characteristics of Included Studies Authors Drug(s) Drug range or mean dosage (mg) Concomitant anxiolytics Study duration (weeks) Time considered in our as endpoint Number of subjects (ITT) % female Mean Age Comorbidities Patients having INSOMNIA as side effect Patients having SOMNOLENCE as side effect Sponsor (Abbasi et al. 2012)() Sertraline + Placebo 200 No 6 T6 20 30 34.2±6.9 No 1 - No (Abolfazli et al. 2011)() Fluoxetine + Placebo 40 No 6 T6 22 50 33.3±6.1 No 5 - No (Aguglia et al. 1993)() Fluoxetine Sertraline 28 72 Yes 8 T8 48 40 87.5 97.5 58.9±17.3 57.5±15.5 No 2 1 1 4 No (Akhondzadeh et al. 2003)() Fluoxetine 60 No 6 T6 24 62.5 36.2±8.1 No 4 7 No (Akhondzadeh et al. 2009)() Fluoxetine + Placebo 40 No 6 T6 20 60 34.2±4.96 No 4 - No (Akkaya et al. 2006)() Reboxetine Venlafaxine 8 150 No 10 T10 50 43 74 81.4 40.4±10.7 42.0±11.0 No - - 22 1 No (Alvarez et al. 2012)() Venlafaxine Placebo 225 Yes 6 T6 113 105 54.9 65.7 45.0±10.3 42.0±10.9 No 14 5 - - Yes (Amini et al. 2005)() Fluoxetine Mirtazapine 20 30 Yes 6 T6 15 16 60 68.8 37.7±11.3 35.0±10.6 No - - 2 6 No (Andreoli et al. 2002)() Reboxetine Fluoxetine 8-10 20-40 Yes 8 T8 126 127 67 65 40.0±.12.0 40.0±.11.5 No 23 15 - - No trial
JCP_00_00_2015_03_31_SERRETTI_JCP14173_SDC1.docx